XTLB (XTL Biopharmaceuticals Ltd. American Depositary Shares) Stock Analysis - AI Report
XTL Biopharmaceuticals Ltd. American Depositary Shares (XTLB) is a publicly traded Healthcare sector company. As of May 21, 2026, XTLB trades at $2.52 with a market cap of $6.39M and a P/E ratio of 0.00. XTLB moved -2.57% today. Year to date, XTLB is +1.34%; over the trailing twelve months it is -43.64%. Its 52-week range spans $2.12 to $10.28. Rallies surfaces XTLB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What is the AI research view on XTLB?
Rallies AI research for XTLB combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
EDELMAN JOSEPH sold 9.60M (~$1.47M) on Nov 19, 2008.
EDELMAN JOSEPH sold 24.68M (~$3.48M) on Nov 18, 2008.
EDELMAN JOSEPH sold 2.70M (~$412.02K) on Nov 18, 2008.
XTLB Analyst Consensus
XTLB analyst coverage data. Average price target: $0.00.
Common questions about XTLB
What is the AI research view on XTLB?
Rallies AI research for XTLB combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
What data powers the Rallies AI report for XTLB?
Rallies AI research for XTLB combines live market data, financials, news, analyst context, hedge fund ownership, politician disclosures, insider activity, and risk factors.
Is XTLB research on Rallies investment advice?
No. Rallies provides research, data, and educational context for XTLB. It does not provide personalized investment advice.